Spinal dural arteriovenous fistula (sDAVF) is often misdiagnosed as an inflammatory or a neoplastic myelopathy, often because of intraparenchymal gadolinium enhancement on magnetic resonance imaging (MRI); proper early diagnosis is important because deficits are reversible and a delay in treatment is associated with permanent morbidity. Tortuous flow voids on MRI are not universally present; thus, recognition of a unique gadolinium enhancement pattern may also aid in the early recognition and treatment of sDAVF.
S
pinal dural arteriovenous fistulas (sDAVFs) are a rare cause of myelopathy with heterogeneous clinical and radiographic features [1] [2] [3] ; they are often mistaken for an inflammatory or a neoplastic myelopathy. 2, 4 Recognizing an sDAVF early is important because clinical deficits are reversible and a delay in diagnosis is associated with severe permanent morbidity. 2 Although abnormal vascular flow voids are a critical radiographic feature that distinguishes sDAVF from other myelopathies, 3 they
are not universally present. Thus, we should be cognizant of other clinical and radiographic features in sDAVF that may facilitate its timely diagnosis. Although spinal cord gadolinium enhancement typically raises concern for transverse myelitis 4 or a neoplasm, 5 it also occurs in a number of noninflammatory myelopathies, 4, 6 including sDAVF. 7 In sDAVF, the gadolinium enhancement pattern on magnetic resonance imaging (MRI) is typically described as nonspecific and hazy. 8 Recently we have noticed an unusual MRI pattern in sDAVF in which abrupt pieces or segments are seemingly missing amidst an intense area of contrast enhancement, a finding we term the missing-piece sign. We sought to assess the frequency of this finding in a pretreatment group of patients with sDAVF and in a large control group of patients with myelopathies of alternative specific causes.
Methods
We retrospectively evaluated 80 patients referred to the Mayo Clinic, Rochester, Minnesota, from January 1, 1997, through December 31, 2017, with a confirmed diagnosis of sDAVF. All pretreatment MRIs were assessed for the presence of gadolinium enhancement and the missing-piece sign, which was defined as at least 1 focal geographic nonenhancing area within a long (>2 vertebral segments) segment of intense holocord (whole cross-sectional area of spinal cord) gadolinium enhancement; findings were verified by a neurologist (N.L.Z.) and a neuroradiologist (W.B.). Neuroimaging was performed with 1.5-T and 3-T MRI machines. Images from diagnostic centers outside the Mayo Clinic were reviewed and compared with Mayo Clinic MRIs. Typical sequences for evaluation of myelopathy include sagittal T1-and T2-weighted, short-tau inversion recovery and axial T2-weighted sequences. Gadolinium was administered at the discretion of the ordering and performing services. The institutional review board of the Mayo Clinic approved this study, and patients provided written consent for the use of their records for medical research. The control group of 144 patients with MRIs and a confirmed alternative myelopathy diagnosis that included a gadolinium-enhancing spinal cord lesion were also assessed for this particular radiographic feature. Diagnoses included spinal cord sarcoidosis in 21 patients, spondylotic compressive myelopathy treated surgically with stability or resolution in 20, intramedullary spinal cord lymphoma in 18, multiple sclerosis in 17, neuromyelitis optica with aquaporin 4-IgG seropositivity in 17, ependymoma in 17, myelitis with myelin oligodendrocyte glycoprotein-IgG seropositivity in 13, spinal cord metastases in 12, and astrocytoma in 9. 
Key Points
Question Does a gadolinium-enhanced magnetic resonance imaging pattern help in distinguishing a spinal dural arteriovenous fistula from other causes of myelopathy?
Findings This medical record review included 51 patients with a spinal dural arteriovenous fistula and pretreatment magnetic resonance imaging with gadolinium. Of these, 44 (86%) had intraparenchymal contrast enhancement, and 19 of these patients (43%) displayed the missing-piece sign defined by at least 1 focal geographic nonenhancing area within a long segment of intense holocord gadolinium enhancement.
Meaning Identifying this unique radiographic finding could potentially result in earlier time to angiography with improved outcomes for patients with spinal dural arteriovenous fistulas. 
Results
Of our group of 80 patients with a confirmed sDAVF, 51 had a pretreatment MRI available to review in which gadolinium was administered. Forty-four of 51 patients (86%) had intraparenchymal contrast enhancement, and 19 of these patients (43%) displayed the characteristic missing-piece sign ( Figure 1) . Of these 19 patients, symptom onset occurred at a median age of 67 years (range, 27-80 years). Fifteen patients were men and 4 were women. Progressive myelopathy features affecting the lower extremities occurred during a median of 33 months (range, 1-84 months), with symptoms including sensory loss (n = 18), weakness (n = 17), urinary tract problems (n = 13), back and/or leg pain (n = 11), and exertional worsening of deficits (n = 8). Eleven patients (58%) received an alternative diagnosis before confirmation of sDAVF, including probable spinal cord tumor in 5 (1 with a spinal cord biopsy), lumbar spondylosis with radiculopathy in 2, peripheral neuropathy in 2, seronegative neuromyelitis optica in 1, and motor neuron disease in 1.
Among patients with the missing-piece sign, prominent perimedullary surface veins seen as tortuous flow voids were not universally present ( Figure 1C The remaining patient had 2 angiograms with normal findings, and sDAVF was identified at the time of durotomy for a planned spinal cord biopsy. Gadolinium enhancement in those patients with sDAVF without the missing-piece sign was generally nonspecific and hazy with some central canal prominence. All patients with identification of an sDAVF were treated with endovascular or surgical occlusion of the fistula; the subsequent course with expected clinical and radiographic response ruled out alternative causes of myelopathy. Six of 8 patients with posttreatment MRIs available to review from our institution (median, 10 months; range, 3-29 months) showed similar or less residual T2-hyperintense signal and preserved spinal cord volume at the site of missing gadolinium enhancement compared with the adjacent spinal cord; correlation was indeterminate in the other 2 patients. The missing-piece sign was not seen in any patients from the control group, but other typical gadolinium enhancement patterns were seen that were helpful clues to an alternative myelopathy diagnosis (Figure 2) . 
Discussion
Spinal cord gadolinium enhancement was common (86%) in our pretreatment group of patients with sDAVF; furthermore, many patients demonstrated a unique pattern of enhancement termed the missing-piece sign that was not seen in a large control group with alternative myelopathies, suggesting specificity for sDAVF. As in other causes of myelopathy, spinal cord contrast enhancement occurs owing to breakdown of the blood-cord barrier, allowing leakage of gadolinium into the parenchyma, which in sDAVF is secondary to progressive venous hypertension. We suspect the peculiar imaging pattern of the missing-piece sign may be owing to inconsistency of the intrinsic venous system of the spinal cord, 3 with the abrupt segments without enhancement likely having better venous egress routes than the adjacent cord with contrast enhancement. Recognition of particular gadolinium enhancement patterns of the spinal cord that may suggest a specific diagnosis is important, 4 especially in the context of sDAVF, where a misdiagnosis as an inflammatory or neoplastic myelopathy is common, as shown in this study and others, 2 and can result in unnecessary harm, with corticosteroid therapy known to worsen sDAVF 2 and spinal cord biopsy with its inherent risk.
As displayed in Figure 2 , helpful gadolinium enhancement patterns have been described in compressive myelopathy (a pancakelike transverse band [width of enhancement greater than the height, enhancement just below maximal stenosis]), 6 multiple sclerosis (homogeneous or ring), 9 5 Identification of particular imaging findings can help physicians pursue the correct subsequent diagnostic or therapeutic steps in a timely manner (eg, obtaining computed tomography of the chest for sarcoidosis vs urgent surgical decompression for compressive myelopathy). Although some myelopathy origins often have particularly helpful contrast enhancement patterns, others are nonspecific and can be highly variable (eg, lymphoma, astrocytoma, myelin oligodendrocyte glycoprotein IgG-seropositive myelitis). In the case of sDAVF, however, recognition of the contrast-enhancing pattern termed the missingpiece sign could result in an earlier time to angiography with improved patient outcomes. Our study is limited by its retrospective design, relatively small numbers, and the variability in imaging protocols and timing.
Conclusions
We have described a unique gadolinium enhancement pattern in sDAVF that we have not seen in a large control group or in other patients with myelopathy at our institution. Identifying the missing-piece sign on MRI may serve as an important piece of the puzzle in solving the diagnosis of sDAVF.
